Insider
📈 Stocks
Inhibrx CEO Mark Lappe Purchases $2.6M in Shares Following Trial Success
(54 days ago)
CEO Mark Lappe's $2.6 million share purchase underscores internal optimism at Inhibrx Biosciences as the clinical-stage firm advances its proprietary protein engineering…